Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Perhaps things are beginnning to look up.

"BioProgress plc announces strategic joint development agreement with Uluru Inc.

Cambridge, UK, 4 May 2006 BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the
speciality pharma and healthcare company, today announced that it has signed a
joint strategic development agreement with the emerging speciality
pharmaceutical company, Uluru Inc. The companies will initially work together
to develop an anti-emetic product for the relief of nausea, using a combination
of BioProgress' film technology and Uluru's Oradisc drug delivery technology.
This relationship will then go on to develop further therapeutic products.

Uluru Inc. is focused on the development of a portfolio of wound management,
plastic surgery and oral care products to provide patients and consumers
improved clinical outcomes through controlled delivery. Uluru's OraDisc
technology is an innovative erodible film technology that sticks to mucous
membranes and allows sustained release of actives into the systemic
circulation over a period of several hours.

The new products are expected to resemble BioProgress' in-the-mouth range of
films strips, which can dissolve instantly, releasing the embedded active
ingredients. However, by adding the Oradisc technology to these films, the
resulting products will not only be fast acting, but will also offer sustained
release of actives over several hours. These new products will therefore have
properties that neither technology could achieve on its own.

Patients with nausea are often unable to take tablets effectively, so an
in-the-mouth instant release anti-emetic offers a good solution to treat acute
nausea and the OraDisc technology provides a longer term solution to the
problem. This is a therapeutic area with a large unmet need. BioProgress has a
large amount of in-house expertise in this area and Uluru has significant
experience in development of film technology through FDA approval.

Richard Trevillion, CEO of BioProgress, said: "We are delighted to be entering
a strategic partnership with Uluru Inc. The technologies from both companies
are complimentary and can work in combination to create products with both
instant release and sustained release characteristics. This approach has the
potential to create real therapeutic value and enhance the effectiveness of
medicines."

Kerry Gray, CEO of Uluru Inc. said: "This partnership is exciting for both
companies as we can access the development strengths and resources of both
groups. Our ability to combine instant release with sustained delivery over an
extended period has the potential to create considerable value. We will be
applying proven technologies to existing medicines with the objective of
dramatically improving the resultant profile."

+ + +

About BioProgress plc:
BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the
company has over 80 patents granted or in application within 24 patent families
and has product development agreements and strategic alliances with several
global companies. As a virtually integrated business, BioProgress has acquired
sales and marketing resources within Europe and the US as a launch mechanism
for its own pharmaceutical products. The business continues to develop
innovative delivery mechanisms using its XGEL polymer technology, replacing
the need to use animal-derived gelatine in pharmaceutical and healthcare
products. For further information please go to
www.bioprogress.com


About Uluru Inc.:
Uluru Inc. is an emerging speciality pharmaceutical company focused on the
development of a portfolio of wound management plastic surgery and oral care
products to provide patients and consumers improved clinical outcomes through
controlled delivery utilizing its innovative transmucosal delivery system and
Hydrogel Nanoparticle aggregate technology.

This press release contains certain statements that are forward-looking within
the meaning of Section 27a of the Securities Act of 1933, as amended, and that
involve risks, and uncertainties, including but not limited to statements made
relating to the establishment of a sales and marketing organization, the
marketing of three additional products and the achievement of a listing on
NASDAQ or an exchange. These statements are subject to numerous risks,
including but not limited to the risks detailed in the Company's Annual Report
on Form 10-K, for the year ended December 31, 2004, Quarterly Report on Form
10-Q for the quarter ended September 30, 2005 and other reports filed by us
with the Securities and Exchange Commission

For further information please contact:

BioProgress plc +44 (0) 1223 394250
Richard Trevillion, Chief Executive Officer

Northbank Communications +44 (0) 207 886 8150
Sue Charles
Gemma Bradley
Justine Lamond

A statement designed to stem the continuing fall in Bioprogress' share price failed to make an impact. The speciality pharmaceutical and healthcare company said that it remained confident of its prospects, confirming its expectation of further positive newsflow in the near term. The group put the recent decline in its share price down to the volatility in the wider market. However, the company has never attracted a significant degree of stability in its share price, so the recent swings are probably just as much company related Bioprogress related. Its shares finished the session 2p easier at 41p.

KD.

doe's anyone hold any rgt. good news today. buys are up.

Richard Trevellion is in the States this week, investors are expecting good news and a rising sp.

RT
18th May

The directors remain extremely confident in the prospects of the group and
anticipate further positive newsflow resulting from the continued
implementation of the Company's strategy, in the near term.

It's in the bag.

Be quick!

"The Company is already enjoying strong organic growth in all business areas and the
outlook for the remainder of this year is [ extremely] positive." (RT 12/04/2006) >

don't get bpgged down by the past. The last six months have seen massive restructuring. stable sp and great prospects

is anyone else here for the free L2?

doesn't look like it papa!

new website launch on monday

.

http://www.bioprogress.com/about

How many 'big pharma' companies are you in discussions with regarding the TABWRAP technology?

We are currently in discussions with four of the top ten pharma companies, and also with a large number of speciality and mid-sized pharmaceutical companies. These discussions will focus on product improvements and profiles where BioProgress will benefit from the sales of the products themselves. Most of the market sizes are blockbuster in size - over $1bn.

http://www.bioprogress.com/investor/faq.php#11

rumour of a deal driving this forward

.................and so we enter the fourth year of the hype that is BPRG.

;-)))))))

AL, It seems they must be listening to you.

Should increase the price a little. I have waited long enough.

BioProgress sees two tablet coating developments generating revenues in 2007
AFX


LONDON (AFX) - BioProgress PLC said the first TabWrap tablet-coating machine, one of the company's core experimental technologies, will be placed in a certified manufacturing facility in the last quarter of the year for initial testing.

At the same time the speciality pharma and healthcare company announced it has developed a new enteric (relating to the intestines) tablet-coating system, called EntWrap.

The company predicted that both developments will generate revenues next year. It plans to market the products itself or in partnership with other pharmaceutical companies.

TabWrap coats solid tablet cores with a non-gelatin layer of film called XGEL, and will compete against the gelatin-coated tablet market.

The company, which says it is working with a number of 'leading pharmaceutical companies' in developing products utilising the TabWrap, will start stability trials in the first half of next year.

Meanwhile the market potential for enteric coated tablets, a key component for a number of prescription medicines, is significantly greater than the gelatin coating market, BioProgress said.

Enteric coatings enable tablets to pass through the acidic stomach environment and into the intestines, where active ingredients can be more rapidly absorbed.

The coating system uses both XGEL and TabWrap technology, which the company claimed will have a number of significant advantages over current enteric coating processes.

'The development of EntWrap widens the market opportunity for BioProgress,' chief executive Richard Trevillion said in a statement.

'With the installation of the first TabWrap machine later this year, we anticipate an aggressive development program of products.'

AIM-listed BioProgress shares closed Tuesday at 46 pence, valuing the company at 65 mln stg.

amy.brown@afxnews.com


UK smallcap opening - BioProgress up on enabling technology update
AFX


LONDON (AFX) - BioProgress moved up 3 pence to 49 after the speciality pharma and healthcare company revealed it has developed a novel enteric tablet-coating system, EntWrap.

Additionally, the company said the first TabWrap tablet-coating machine is due to be placed into a cGMP pharmaceutical tablet manufacturing facility within the UK in Q4 2006 for a series of initial validation tests.

Following the news, Bridgewell's Chris Millington reiterated his 'buy' recommendation, pointing out that there is still upside to go to his 57 pence fair value on the stock.

newsdesk@afxnews.com

fjb/vjt

Can somebody list all the 'unsuitable' executives that have progressed through BPRG's revolving doors in last year or so, preferably those carrying large bags with them.

Interesting information on Web. It will very nice if this is true.

http://www.bioprogress.com/news/article.php?News_ID=521462

CFO resignation is yet another careless moment. The company seems to have bumbled along from 1 problem to another for so long.

Come along Big Al, come clean and tell us that you hold some BPRG :)

No-one here seems to have commented on the interim statements which were intriguing indeed. Enough to persuade me to re-invest at 47p after a couple of years out.

Interim statement here

The business is very differently structured now from its overblown days under Graham Hind. To me it looks like there's more realism and substance about it.

The likeness between Spinal Tap's drummers and BPRG's FDs is the one concern I guess!

See you hopefully at the Xmas gig!

Hi Bones.

Never did buy them. Old habits die hard I guess. ;-) Must agree the company is a very different animal these days. Wonder if the shareholders are. LOL! I get the impression there's no rush to jump in however, so we'll see.

Best of luck with it.